Article

Dr. Strosberg on the Results of the NETTER-1 Trial

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.

Jonathan Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the results of the NETTER-1 trial.

The NETTER-1 trial compared Lutathera (lutetium Lu 177 dotatate) with high-dose octreotide (Sandostatin) in patients with midgut neuroendocrine tumors (NETs). It is the first phase III prospective randomized clinical trial evaluating Lutathera in this patient population.

The primary endpoint of the trial was progression-free survival (PFS). The study demonstrated a 79% improvement in the hazard ratio for PFS. The PFS for the control arm (high-dose octreotide) was 8 months. At the time of the primary endpoint analysis, PFS had not yet been reached with Lutathera.

Results of the trial also demonstrated a 60% improvement in overall survival (OS) (P = .004). While this result did not reach the threshold for statistical significance, it is only an interim analysis, and Strosberg remains hopeful that a final analysis of OS will see clinically and statistically significant improvement.

Related Videos
Ami Umesh Badami, MD, medical oncologist, Endeavor Health Medical Group
Phillip Phillip, MD
Katherine L. Nathanson, MD
PEDRO BARATA, MD
Anthony M. Hunter, MD
Thomas Westbrook, MD, assistant professor, Department of Internal Medicine, Rush University
John K. Lee, MD, PhD, associate professor-in-residence, Division of Hematology/Oncology, Department of Medicine; the Institute for Urologic Oncology, Department of Urology, the David Geffen School of Medicine, UCLA Heath
Tae Min Kim, MD, PhD
Whitney Goldsberry, MD
Syed Abbas Ali, MBBS